Resilience Therapeutics raises $975,000 to target PTSD.
Resilience Therapeutics, a US-based life sciences firm led by former Navy Seal Jeff Sabados, has raised $975,000 out of an overall planned $3m raise in a bid to developing a cure for post-traumatic stress disorder (PTSD).
Investors in the round include research lab PsychoGenics and Jason Fuller, principal at New Enterprise Associates. Resilience hopes to close the remaining $2m by the end of March.
Resilience is licensing intellectual property from Emory, Vermont, and Tulane universities, as well as the Scripps Research Institute, and will be committing the cash to performing pre-clinical research over the next year.
PTSD affects millions of Americans, and presents a major problem for war veterans – affecting up to 20% of the 2.6 million servicemen deployed to Iraq and Afghanistan.
Jason Fuller told news provider Bizjournals: “There’s an obvious, huge unmet clinical need. Everyone has traumatic experiences at some point and many will develop a stress-related disorder […] but Resilience Therapeutics is joining the academic thought leaders in trying to understand the biology and use that to eventually develop really great drugs.”
